UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K/A
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
| | | |
| Date of Report (Date of Earliest Event Reported): | | November 4, 2004 |
CHAD Therapeutics, Inc.
__________________________________________
(Exact name of registrant as specified in its charter)
| | | |
| California | 001-12214 | 34-1659805 |
_____________________
(State or other jurisdiction | _____________
(Commission | ______________
(I.R.S. Employer |
| of incorporation) | File Number) | Identification No.) |
| | | |
| 21622 Plummer St, Chatsworth, California | | 91311 |
_________________________________
(Address of principal executive offices) | | ___________
(Zip Code) |
| | | |
| Registrant’s telephone number, including area code: | | 818-882-0883 |
Not Applicable
______________________________________________
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02. Results of Operations and Financial Condition.
On November 4, 2004, CHAD Therapeutics, Inc. issued a press release announcing our financial results for the quarter ended September 30, 2004. This amendment includes the financial results which were inadvertantly not attached with CHAD Therapeutics, Inc.'s 8K filing of the same date,
In accordance with General Instruction B.2 of From 8-K, the information in this Form 8-K and the exhibit attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, unless CHAD Therapeutics, Inc. specifically incorporates the foregoing information into those documents by reference.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | |
| | | CHAD Therapeutics, Inc. |
| | | | | |
| March 8, 2005 | | By: | | Earl L. Yager
|
| | | | |
|
| | | | | Name: Earl L. Yager |
| | | | | Title: Chief Executive Officer |
| | | | | |
| | | CHAD Therapeutics, Inc. |
| | | | | |
| March 8, 2005 | | By: | | Tracy A. Kern
|
| | | | |
|
| | | | | Name: Tracy A. Kern |
| | | | | Title: Chief Financial Officer |
Exhibit Index
| | | |
| Exhibit No. | | Description |
| |
|
99.01 | | Second Quarter Financial Results Press Release |
